Pimecrolimus is a calcineurin inhibitor developed for the topical treatment of atopic dermatitis. It selectively targets T cells and mast cells, but since it has no effects on dendritic cells, endothelial cells and fibroblasts, it does not induce skin atrophy. Pimercolimus was effective, well-tolerated and safe in infants, children and adolescents with mild to moderate atopic dermatitis in several randomized control trials. Given the low capacity of the drug to permeate through the skin, there is no evidence of systemic immunosuppression from topical pimecrolimus therapy.

The efficacy and safety of topical pimecrolimus in pediatric patients with atopic dermatitis.

GISONDI, Paolo;GIROLOMONI, Giampiero
2005-01-01

Abstract

Pimecrolimus is a calcineurin inhibitor developed for the topical treatment of atopic dermatitis. It selectively targets T cells and mast cells, but since it has no effects on dendritic cells, endothelial cells and fibroblasts, it does not induce skin atrophy. Pimercolimus was effective, well-tolerated and safe in infants, children and adolescents with mild to moderate atopic dermatitis in several randomized control trials. Given the low capacity of the drug to permeate through the skin, there is no evidence of systemic immunosuppression from topical pimecrolimus therapy.
Atopic dermatitis; Pediatric patients; Pimecrolimus; Treatment
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11562/304638
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 1
  • ???jsp.display-item.citation.isi??? ND
social impact